Lowenstein Sandler represented Jefferies LLC, TD Securities (USA) LLC, and Piper Sandler & Co. as joint bookrunning managers in Nektar Therapeutics’ (NASDAQ: NKTR) $460 million underwritten public offering of shares of common stock and pre-funded warrants.
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
Jefferies, TD Securities, and Piper Sandler are investment banking and capital markets firms that provide advisory, sales and trading, and research services to corporate and institutional clients.
The Lowenstein team included Steven M. Skolnick, James C. Shehan, Evyn Rabinowitz, and Adesimisola Tijani.
